Please wait while the formulary information is being retrieved.
RETROVIR (ZIDOVUDINE)
- HIV infection
- Prevention of maternal-fetal transmission of HIV
- Zidovudine Syrup
- Zidovudine Oral Syrup
- Zidovudine Capsule
- Retrovir Oral Syrup
- Retrovir Intravenous Solution
- Retrovir Capsule
- By Indication
10 mg/mL oral syrup
- 20 milliliters (200 mg) by oral route every 8 hours
10 mg/mL oral syrup
- 20 milliliters (200 mg) by oral route every 8 hours
100 mg capsule
- 2 capsules (200 mg) by oral route every 8 hours
10 mg/mL oral syrup
- 20 milliliters (200 mg) by oral route every 8 hours
10 mg/mL intravenous solution
- Infuse 1 mg/kg over 1 hour(s) by intravenous route every 4 hours 5 times per day
100 mg capsule
- 2 capsules (200 mg) by oral route every 8 hours
HIV infection
- Infuse 1 mg/kg over 1 hour(s) by intravenous route every 4 hours 5 times per day
- Infuse 1 mg/kg over 1 hour(s) by intravenous route every 4 hours 6 times per day
- 1 capsule (100 mg) by oral route every 4 hours
- 1 capsule (100 mg) by oral route every 4 hours 5 times per day while awake
- 10 milliliters (100 mg) by oral route every 4 hours
- 10 milliliters (100 mg) by oral route every 4 hours 5 times per day while awake
- 20 milliliters (200 mg) by oral route every 8 hours
- 2 capsules (200 mg) by oral route every 8 hours
- 30 milliliters (300 mg) by oral route every 12 hours
Prevention of HIV infection after exposure
- 1 capsule (100 mg) by oral route every 4 hours
- 1 capsule (100 mg) by oral route every 4 hours for 28 days
- 10 milliliters (100 mg) by oral route every 4 hours
- 10 milliliters (100 mg) by oral route every 4 hours for 28 days
- 20 milliliters (200 mg) by oral route every 8 hours
- 20 milliliters (200 mg) by oral route 3 times per day
- 2 capsules (200 mg) by oral route 3 times per day for 28 days
- 2 capsules (200 mg) by oral route every 8 hours for 28 days
- 2 capsules (200 mg) by oral route every 8 hours
- 20 milliliters (200 mg) by oral route 3 times per day for 28 days
- 20 milliliters (200 mg) by oral route every 8 hours for 28 days
- 2 capsules (200 mg) by oral route 3 times per day with food
- 30 milliliters (300 mg) by oral route 2 times per day
- 30 milliliters (300 mg) by oral route every 12 hours
- 30 milliliters (300 mg) by oral route 2 times per day for 28 days
- 30 milliliters (300 mg) by oral route every 12 hours for 28 days
Prevention of maternal-fetal transmission of HIV
- Infuse 2 mg/kg over 1 hour(s) by intravenous route followed by a continuous infusion of 1 mg/kg/hr until clamping of the umbilical cord
- 1 capsule (100 mg) by oral route 5 times per day until the startof labor
- 10 milliliters (100 mg) by oral route 5 times per day until the start of labor
- 2 capsules (200 mg) by oral route every 8 hours until the start of labor
- 20 milliliters (200 mg) by oral route every 8 hours until the start of labor
- None
Contraindicated
- Adriamycin
- Adriamycin Pfs
- clozapine
- Clozaril
- Copegus
- Cytovene
- deferiprone
- Doxil
- doxorubicin
- doxorubicin HCl peg-liposomal
- Fazaclo
- Ferriprox
- ganciclovir sodium
- Lipodox
- Lipodox 50
- Moderiba
- Moderiba Dose Pack
- Rebetol
- Ribapak Dose Pack
- Ribasphere
- Ribatab Dose Pack
- ribavirin
- stavudine
- Versacloz
- Virazole
- Zerit
Severe
Moderate
- colchicine-probenecid
- Diskets
- Dolophine
- methadone
- Methadone Intensol
- Methadose
- probenecid
- Lactating mother
- Lactic acidosis
- Severe hepatic disease
Contraindicated
- Anemia
- Bone marrow depression
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hepatomegaly
- Myopathy
- Myositis
- Neutropenic disorder
Severe
Moderate
- Disease of liver
- Toxic amblyopia
RETROVIR (ZIDOVUDINE)
- HIV infection
- Prevention of maternal-fetal transmission of HIV
- Anemia
- Leukopenia
- Neutropenic disorder
- Anorexia
- Cough
- Fever
- Headache disorder
- Insomnia
- Malaise
- Myalgias
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- Abdominal pain with cramps
- Arthralgias
- Chills
- Constipation
- Dyspepsia
- Fatigue
- General weakness
- Macrocytosis
- Nail discoloration
- Peripheral sensory neuropathy
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Aplastic anemia
- Cardiomyopathy
- CNS toxicity
- Hemolytic anemia
- Hepatitis
- Jaundice
- Lactic acidosis
- Macular retinal edema
- Manic disorder
- Myopathy
- Myositis
- Pancreatitis
- Pancytopenia
- Pure red cell aplasia
- Rhabdomyolysis
- Seizure disorder
- Steatosis of liver
- Stevens-johnson syndrome
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
- Vasculitis
Less Severe
- Acute confusion
- Amblyopia
- Depression
- Dizziness
- Drowsy
- Dyschromia
- Dysgeusia
- Dysphagia
- Dyspnea
- Flatulence
- Flu-like symptoms
- Gynecomastia
- Hearing loss
- Hyperbilirubinemia
- Hyperhidrosis
- Hyperpigmentation of oral mucosa
- Increased urinary frequency
- Lipodystrophy
- Lymphadenopathy
- Paresthesia
- Photophobia
- Pruritus of skin
- Rhinitis
- Sinusitis
- Symptoms of anxiety
- Syncope
- Tremor
- Urinary hesitancy
- Urticaria
- Vertigo
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Zidovudine
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Contraindicated
Zidovudine
Cdc does not recommend breastfeeding in hiv-positive women
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Zidovudine has caused severe blood problems including a decrease in red blood cells (anemia) and white blood cells (neutropenia). They occur more frequently in people with advanced HIV disease (AIDS). Blood problems may require blood transfusions or stopping your medication.<br /><br />Your doctor will order blood tests to monitor for this. Keep all medical appointments. Seek immediate medical attention if you develop signs of anemia (unusual tiredness, breathing problems, weakness, bluish fingernails/lips, pale skin, fast heartbeat).<br /><br />Low white blood cells can make you more likely to get serious (sometimes fatal) infections. Seek immediate medical attention if you develop signs of infection such as fever, chills, persistent cough, breathing problems, or sore throat. This medication may also cause muscle problems (myopathy).<br /><br /> Seek immediate medical attention if you develop symptoms of myopathy (such as wasting or decrease in muscle size, muscle weakness/pain/tenderness, weight loss). Rarely, zidovudine has caused a severe (sometimes fatal) liver and blood problem (lactic acidosis). Tell your doctor right away if you develop symptoms of liver problems (persistent nausea, stomach/abdominal pain, dark urine, yellowing eyes/skin) or lactic acidosis (rapid breathing, drowsiness, muscle aches). These serious side effects may occur more often in women and obese patients.
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| Prevention of maternal-fetal transmission of HIV | |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool